{"protocolSection":{"identificationModule":{"nctId":"NCT06476535","orgStudyIdInfo":{"id":"29BRC24.0155 - OPIUM"},"organization":{"fullName":"University Hospital, Brest","class":"OTHER"},"briefTitle":"Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy","officialTitle":"Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy","acronym":"OPIUM"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-05-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-05-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-13","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University Hospital, Brest","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The study will collect cases of MPN patients who also benefit from an anti-inflammatory immunotherapy for another disease. Efficacy and tolerability of the drug will be assessed in this population."},"conditionsModule":{"conditions":["Myeloproliferative Neoplasm","Inflammatory Disease"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Efficacy of the anti-inflammatory immunotherapy","description":"Depending on the indication of the anti-inflammatory treatment, clinical efficacy will be assessed clinically as number of patients reaching complete (total disappearance of initial symptoms- diarrhea, arthritis, fever, skin lesions), partial (improvement of symptoms, but not total disappearance) or absence of response (the treatment did not improve the symptoms). Clinical judgement will be according to the physician appreciation.","timeFrame":"1 year"},{"measure":"Tolerability of the anti-inflammatory immunotherapy","description":"Tolerability will be assessed as the number of reported unexpected side effects attributed to the treatment as judged by the caring physician, including treatment discontinuation","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* MyeloProliferative Neoplasm diagnosis\n* receiving or having received an immunotherapy targeting IL-1, IL-6, IL-17, IL-23 or TNF\n\nExclusion Criteria:\n\n* Unable to consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"MyeloProliferative Neoplasm patients followed in one of the centres participating to the FIM (French Intergroup- MPN) group","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Chu Brest","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.3903,"lon":-4.48628}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"All collected data that underlie results in a publication","infoTypes":["STUDY_PROTOCOL"],"timeFrame":"Data will be available beginning three years and ending fifteen years following the final study report completion","accessCriteria":"Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009369","term":"Neoplasms"},{"id":"D000009196","term":"Myeloproliferative Disorders"}],"ancestors":[{"id":"D000001855","term":"Bone Marrow Diseases"},{"id":"D000006402","term":"Hematologic Diseases"}],"browseLeaves":[{"id":"M12149","name":"Myeloproliferative Disorders","asFound":"Myeloproliferative Neoplasms","relevance":"HIGH"},{"id":"M5134","name":"Bone Marrow Diseases","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"T1311","name":"Chronic Myeloproliferative Disorders","asFound":"Myeloproliferative Neoplasms","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M2853","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M4217","name":"Anti-Inflammatory Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"}]}},"hasResults":false}